Weight-loss drugs may lower cancer risk in people with diabetes, a study suggests Illustration of a semaglutide peptide (blue) bound to its target glucagon-like peptide-1 (GLP-1, light pink).

Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related ...

Participants in a new study who used GLP-1 drugs had a much lower cancer risk than those who had bariatric surgery.

GLP-1 drugs like Ozempic may lower the risk of obesity-related cancers, particularly colorectal cancer, among type 2 diabetes ...

Game-changing weight loss jabs could help ward off up to 14 types of cancer, world-leading experts suggest. Mounjaro, Ozempic and other ... such as slashing the risk of heart attacks, strokes ...

Recent studies suggest that popular weight loss drugs like Ozempic may offer surprising anti-cancer benefits, particularly ...

First-generation GLP-1 drugs like liraglutide (Saxenda) and exenatide (Byetta) were associated with a 41% lower risk of ...

Recent research suggests that Ozempic and other GLP-1 receptor agonists, commonly used for weight loss, may offer unexpected ...

Weight-loss drugs and bariatric surgery both have an impact on cancer risk. A new study breaks down the link and how GLP-1 ...

Weight loss jabs could reduce the risk of up to 14 types of cancer, new research has found. Mounjaro, Ozempic and other ...

Weight-loss injections could cut the risk of cancer by almost half, research suggests. Researchers analysed the health ...

Being overweight or obese is the second biggest cause of cancer in the UK, causing more than one in 20 cancer cases, ...